Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Skuldtech Secures EUR 1 Million to Develop New Diagnostics for Alzheimer's Disease

Published: Wednesday, September 11, 2013
Last Updated: Wednesday, September 11, 2013
Bookmark and Share
Skuldtech and AB Science to renew their collaboration agreementto bring to market a new treatment for Alzheimer's disease.

Skuldtech announces that it has secured EUR 1 million in funding from Bpifrance (French public financing structure) as part of a project on Alzheimer's disease that has received funding of EUR 8.6 million in total. The program is planned to last for four years, with the first results expected in 2018.
Skuldtech has joined forces with AB Science for this program, with the aim of developing a new therapy for the treatment of Alzheimer's disease. As part of the program, Skuldtech will develop a companion diagnostic for AB Science's masitinib molecule and a diagnostic for the validity of cognitive tests and tests to predict the progression of Alzheimer's disease.

Using blood samples taken as part of the Phase III trial of masitinib in Alzheimer's disease, Skuldtech will identify the blood biomarkers that will help make simple, reliable diagnostic tests available as a matter of routine. This will result in treatments that can be tailored to the patient and the ability to monitor sufferers as their disease progresses. The clinical trial of masitinib was launched in Europe and other countries in May 2013. It expects to recruit a total of 400 patients. Blood samples from these patients will contribute to the development of a companion diagnostic by making it possible to identify those individuals most likely to benefit from the treatment.
This approach has already proven successful in the development of a new treatment for pancreatic cancer that combines gemcitabine and masitinib, where Skuldtech identified new biomarkers predicting a favorable response to treatment. The results of this clinical study led to an application to the European Medicines Agency for Marketing Authorization (MA) for masitinib in combination with companion biomarkers.
Using further blood samples, Skuldtech will also develop a diagnostic for the validity of cognitive tests and tests predicting the progression (slow or rapid) of Alzheimer's disease.
This project builds on Skuldtech's recent success in identifying blood biomarkers associated with a cognitive score. The company identified two sets of new blood markers, each associated with two trisomy 21 patient populations with low and high IQs respectively. The results of this study were published in the European Journal of Human Genetics in February 2013 (i). By describing the blood transcriptional profile of each group, Skuldtech identified specific biomarkers corresponding to a level of response in cognitive tests. The company hopes to emulate this result in the Alzheimer's disease program.
Skuldtech is keen to use the funding to capitalize on its broadband sequencing-based technological platform, pairing it with proprietary bioinformatics and biostatistics programs to measure and confirm the stage of progression of Alzheimer's disease.
“This new partnership to work on Alzheimer's disease will strengthen Skuldtech's position in the field of personalized medicine and in the development of companion diagnostics associated with new treatments in phases of clinical trials,” said Didier Ritter, CEO, Skuldtech. “As well as bringing new diagnostics to market, we are also open to similar partnerships with other biotech companies or with pharmaceutical laboratories.”
Alzheimer's is the most frequently occurring neurodegenerative disease in the world, affecting around 6 per cent of over-65s. In the US, it is the sixth most common cause of mortality in the population.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Skuldtech Identifies New Predictive Markers for Pancreatic Cancer Survival
The companion diagnostic developed by Skuldtech from these biomarkers will make it possible to identify patients most likely to benefit from this new treatment.
Thursday, January 31, 2013
Scientific News
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos